Allergic rhinitis is a chronic immunoglobulin E-mediated respiratory response to environmental allergens. It is typically treated with intranasal corticosteroids, followed by antihistamines, mast cell stabilizers, decongestants, leukotriene antagonists, and/or anticholinergics. Allergen immunotherapy can target specific environmental allergies and work to change the response of the patient’s immune system to the allergen. The biological therapies that target circulating free IgE, such as Xolair, may be a promising novel approach to treating the disease. The availability of allergen immunotherapy and the potential of biological therapies with novel mechanisms of action are expanding physicians’ treatment arsenal and fueling competition in the allergic rhinitis therapy market.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed allergic rhinitis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed allergic rhinitis patients?
- How have allergen immunotherapies and/or biologics been integrated into the treatment algorithm, and what is their source of business?
- What percentage of allergic rhinitis patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of allergic rhinitis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Allergic Rhinitis - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms Allergic Rhinitis US February 2019
Author(s): Matthew W. Scutcher, MEng PhD; Colleen E. Albacker, PhD
Matthew Scutcher is Therapy Leader for the Immune & Inflammatory research team at DRG.
In this role, he leads a team of 13 Research Associates, Business Insights Analysts and Directors responsible for analyzing some of the largest and most dynamic markets in the pharmaceutical industry
He has been with DRG since 2009 and holds a Ph.D. from University College London and a Master’s degree in Chemical Engineering from Imperial College London.
Colleen E. Albacker, Ph.D., is a director with the Immune and Inflammatory Disorders group at Decision Resources Group, where she comanages a team of analysts generating syndicated market research content. She has authored market research reports analyzing physician, payer, and market trends in respiratory indications, including asthma and COPD.
Prior to joining Decision Resources Group, Dr. Albacker conducted her graduate research on chromatin-modifying factors in zebrafish cancer and hematopoietic development at Harvard Medical School and Boston Children’s Hospital. She also gained experience with market research through a fellowship with the Harvard Office of Technology Development. Dr. Albacker holds a Ph.D. in genetics from Harvard University and a B.S. in biology with honors from the Pennsylvania State University.